Voices
Amol Akhade: ASCO26 Abstract on Benmelstobart-Based Regimen in First-Line NSCLC
Amol Akhade/hiranandanihospital.org

Amol Akhade: ASCO26 Abstract on Benmelstobart-Based Regimen in First-Line NSCLC

Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on X:

“ASCO26 LBA8507

Benmelstobart + chemo followed by benmelstobart + anlotinib improved PFS versus tislelizumab + chemo in frontline non-squamous NSCLC:

  • mPFS 14.4 vs 8.3 months
  • HR 0.67 (P=0.0017)
  • Benefit across most subgroups

But the control arm was tislelizumab + chemo, not necessarily the strongest global benchmark. The unanswered question remains: does adding maintenance anti-angiogenic therapy translate into an OS benefit?

For now:

  • PFS positive
  • OS immature

Practice-changing? Not yet.”

Title: A randomized, open-label, parallel-controlled phase 3 trial of benmelstobart plus chemotherapy and anlotinib for first-line treatment of advanced non-squamous non–small cell lung cancer.

Authors: Yuankai Shi, Xiaoyong Tang, Lin Wu, Wei Guo, Yanping Hu, Honghai Wang, Shiguang Xie, Qingshan Li, Yu Yao, Yan Wang

Read the Full Abstract.

Other articles featuring Dr. Akhade on OncoDaily.

Amol Akhade cancer Honghai Wang Lin Wu Lung cancer NSCLC OncoDaily Oncology Qingshan Li Shiguang Xie Wei Guo Xiaoyong Tang Yan Wang Yanping Hu Yu Yao Yuankai Shi